920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
25
7
7
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
20.0%
5 terminated/withdrawn out of 25 trials
16.7%
-69.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (25)
JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
Role: lead
JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies
Role: lead
A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants
Role: collaborator
Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML
Role: lead
C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
Role: lead
Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Solid Tumors
Role: lead
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
Role: lead
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
Role: collaborator
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
Role: lead
Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
Role: lead
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia
Role: lead
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
Role: lead
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
Role: lead
A Study of RD14-01 in Patients With Advanced Solid Tumors
Role: lead
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
Role: lead
CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL
Role: lead
A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies
Role: lead
Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
Role: lead
A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL
Role: lead
UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies
Role: lead